Nanatinostat TFA - CAS 1256448-48-2

Nanatinostat, also known as Tractinostat, CHR-3996 and VRx-3996, is an orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.

Apoptosis, Others, HDAC

Others, Apoptosis, Chromatin/Epigenetic, DNA Damage/DNA Repair

1256398

C22H20F4N6O4

508.43

OC(=O)C(F)(F)F.[H][C@@]12CN(C[C@]1([H])[C@H]2NCc1ccc2cc(F)ccc2n1)c1ncc(cn1)C(=O)NO

-20°C

Ice Packs

Small Compound